Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)

Amylyx Pharmaceuticals (AMLX) has 3 years of Gross Profit data on record, last reported at -$26.9 million in Q4 2024.

  • For Q4 2024, Gross Profit fell 127.11% year-over-year to -$26.9 million; the TTM value through Sep 2025 reached -$26.9 million, down 114.66%, while the annual FY2024 figure was $81.4 million, 77.08% down from the prior year.
  • Gross Profit reached -$26.9 million in Q4 2024 per AMLX's latest filing, down from $416000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $99.1 million in Q4 2023 and bottomed at -$26.9 million in Q4 2024.
  • Average Gross Profit over 3 years is $43.2 million, with a median of $49.2 million recorded in 2022.
  • Peak YoY movement for Gross Profit: soared 22393.33% in 2023, then plummeted 127.11% in 2024.
  • A 3-year view of Gross Profit shows it stood at $19.1 million in 2022, then soared by 419.77% to $99.1 million in 2023, then tumbled by 127.11% to -$26.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gross Profit were -$26.9 million in Q4 2024, $416000.0 in Q3 2024, and $1.0 million in Q2 2024.